Dermatology

In a phase 3 clinical trial, dupilumab met both its primary and key secondary endpoints, demonstrating efficacy as a potential treatment for atopic hand and foot dermatitis.

A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.

Results from a recent phase 3 clinical trial demonstrated topline safety and efficacy results for tapinarof cream, 1% (VTAMA; Dermavant) as a potential treatment for atopic dermatitis in patients 2 years and older.

Following positive results from a phase 3 clinical trial, the FDA has accepted a New Drug Application for berdazimer gel, 10.3% (Novan) for treating patients with molluscum contagiosum.

A supplemental Biologics License Application has been accepted by the FDA for treating adolescents and adults with chronic spontaneous urticaria.

In data presented at the AAAAI annual conference, 5 common contact dermatitis-causing allergens were identified, emphasizing the importance of patch testing.

A New Drug Application has been submitted to the FDA for potential approval of roflumilast foam 0.3% for the treatment of seborrheic dermatitis in adults and adolescents.

A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.

An interview with Victoria Barrio, MD, and Fabiana Castro Porto Silva Lopes, MD, about the Society for Pediatric Dermatology and its efforts to address diversity in the dermatology field.

A 16-year-old boy with developmental delay and intellectual disability developed dramatic chronic wrinkling of his scalp over a year ago. The lesions were persistent but not symptomatic. What's the diagnosis?

A healthy 17-year-old girl with inflammatory acne had failed to respond to topical tretinoin, benzoyl peroxide, and oral minocycline. What's the diagnosis?

Arcutis Biotherapeutics, Inc has submitted a supplemental New Drug Application for roflumilast cream (ZORYVE) to the US Food and Drug Administration for treatment of plaque psoriasis in children aged 2 to 11 years.

A recent article highlighted multiple therapies for treating atopic dermatitis, including many which do not require a prescription.

A recent article highlighted multiple forms of treatment for atopic dermatitis, detailing their benefits and adverse events.

Adults with atopic dermatitis saw improved symptoms when taking dupilumab compared to placebo, regardless of the age when they first presented with the condition.

Pediatric care requires understanding, not only of the disease impact, but also its presentation and management in children.

This brain imaging study was the first to look at the position of depression and systemic inflammation in brain measures while including the largest sample of patients with psoriasis to date.

Recently announced data from the INTEGUMENT-1 phase 3 clinical trial demonstrated positive safety and efficacy results for atopic dermatitis patients 6 years and older treated with roflumilast cream (Arcutis Biotherapeutics).

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

Dermavant Sciences recently announced positive results for VTAMA (tapinarof cream, 1%) for treatment of atopic dermatitis in children aged as young as 2 years.

You are asked to evaluate an African American boy aged 4 years with a birthmark on his back and right arm. He is healthy with normal growth and development. What's the diagnosis?

You are asked to evaluate a healthy 1.5-day-old girl who has a congenital red patch with coarse telangiectasias and a surrounding ring of pallor on the right shoulder. What's your diagnosis?

The parents of a 3-month-old girl seek medical advice regarding recent seizures and a facial birthmark. What’s the diagnosis?

New research suggests the sleep quality of caregivers and patients with atopic dermatitis (inadequately-controlled with topical therapies) may improve with dupilumab treatment.

New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in children and adolescents.

This case study analyzes variants of majocchi granuloma and potential treatment.

At the 2022 AAP National Conference & Exhibition, a presenter delves into diagnosis and management of common and uncommon skin rashes in newborns.

A review examined the ways in which costs can be reduced for patients with varying types of atopic dermatitis.

A previously healthy 11-year-old boy presents with purpuric macules and papules symmetrically distributed on his buttocks and upper and lower extremities. What’s the diagnosis?

In 2 recent phase 3 trials, safety and efficacy was proven in the use of roflumilast cream 0.3% for the treatment of plaque psoriasis.